Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study

• Main Authors: Elisa Lazzaroni (Author), Maria Elena Lunati (Author), Laura Montefusco (Author), Ida Pastore (Author), Enrica Chebat (Author), Vincenzo Cimino (Author), Paola Silvia Morpurgo (Author), Milena Muratori (Author), Laura Plebani (Author), Andrea Bolla (Author), Antonio Rossi (Author), Luciana Vallone (Author), Alessandra Gandolfi (Author), Camilla Tinari (Author), Francesca D'Addio (Author), Moufida Ben Nasr (Author), Cristian Loretelli (Author), Cristiana Scaranna (Author), Rosalia Bellante (Author), Roberto Manfrini (Author), Fabrizio Muratori (Author), Ivano Franzetti (Author), Emanuela Orsi (Author), Carmine Gazzaruso (Author), Renata Ghelardi (Author), Paolo Desenzani (Author), Stefano Genovese (Author), Angela Girelli (Author), Franco Folli (Author), Cesare Berra (Author), Paolo Fiorina (Author)
• Format: Book
• Published: Elsevier, 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Dapagliflozin has been demonstrated to improve glycemic control, blood pressure, and body weight in type 2 diabetes mellitus (T2D); indeed, it can also reduce the risk of progression to renal failure, of hospitalization for heart failure and of cardiovascular death. We aim to investigate the acute e...